Most cited papers from CritiTech (United States)

CritiTech (United States)

What are the most cited papers from CritiTech (United States)?

The most cited paper from CritiTech (United States) is "A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies" (Stephen K. Williamson, Gary Alan Johnson, Holly A. Maulhardt et al., 2015), with 69 citations. Next come "Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac ® ) in a Rodent Model" (24) and "Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies" (20).

Published TypeFieldAccess

Showing 13 of 13 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies Stephen K. Williamson, Gary Alan Johnson, Holly A. Maulhardt et al. · Cancer Chemotherapy and Pharmacology Open access	22 Apr 2015	69
2	Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac ® ) in a Rodent Model James Verco, William Forrest Johnston, Michael Jay Baltezor et al. · Journal of Aerosol Medicine and Pulmonary Drug Delivery Open access	25 Oct 2018	24
3	Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies Shelagh J. Verco, Holly A. Maulhardt, Michael Jay Baltezor et al. · Drug Delivery and Translational Research Open access	6 Nov 2020	20
4	Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer James Verco, William Forrest Johnston, Michael Frost et al. · Journal of Aerosol Medicine and Pulmonary Drug Delivery Open access	26 Jul 2019	15
5	Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs Sandra M. Axiak‐Bechtel, Selting, Decedue et al. · International Journal of Nanomedicine Open access	Oct 2011	15
6	Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies Holly A. Maulhardt, Shelagh J. Verco, Michael Jay Baltezor et al. · Drug Delivery and Translational Research Open access	4 Sep 2022	12
7	Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines Sandra M. Axiak‐Bechtel, Senthil R. Kumar, Kristin K. Dank et al. · Investigational New Drugs	12 Sep 2013	10
8	Preclinical antitumor activity of a nanoparticulate SN38 Mazin Francis Al-Kasspooles, Stephen K. Williamson, David W. Henry et al. · Investigational New Drugs	8 Jan 2013	10
9	Paclitaxel Nanoparticles: Production Using Compressed CO2 as Antisolvent: Characterization and Animal Model Studies Fenghui Niu, Katherine F. Roby, Roger A. Rajewski et al. · ACS symposium series Conference paper	9 Mar 2006	9
10	Evaluation of intravenous and subcutaneous administration of a novel, excipient‐free, nanoparticulate formulation of paclitaxel in dogs with spontaneously occurring neoplasia Kim A. Selting, Sandra M. Axiak‐Bechtel, Jahna Espinosa et al. · Veterinary and Comparative Oncology	4 Sep 2018	8
11	Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment Ian E. Stewart, Phillip G. Durham, Jacob M. Sittenauer et al. · Pharmaceutical Research Open access	16 Sep 2022	7
12	Solvent Removal and Spore Inactivation Directly in Dispensing Vials with Supercritical Carbon Dioxide and Sterilant Jahna Howell, Fengui Niu, Shannon E. McCabe et al. · AAPS PharmSciTech Open access	13 Apr 2012	6
13	Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies Gere S. diZerega, Holly A. Maulhardt, Shelagh J. Verco et al. · Oncology and Therapy Open access	30 Jan 2024	3

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.